|
|
Volumn 23 Suppl 1, Issue , 2005, Pages 1-2
|
|
Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
NEUROLEPTIC AGENT;
RISPERIDONE;
ARTICLE;
COST BENEFIT ANALYSIS;
ECONOMICS;
HUMAN;
PHARMACOECONOMICS;
SCHIZOPHRENIA;
STATISTICAL MODEL;
ANTIPSYCHOTIC AGENTS;
COST-BENEFIT ANALYSIS;
ECONOMICS, PHARMACEUTICAL;
HUMANS;
MODELS, ECONOMIC;
RISPERIDONE;
SCHIZOPHRENIA;
|
|
EID: 33644821818
PISSN: 11707690
EISSN: None
Source Type: Journal
DOI: 10.2165/00019053-200523001-00001 Document Type: Article |
|
Times cited : (7)
|
|
References (0)
|
